Table 1. Baseline demographic and tumor characteristics.

	Total	eIT Alone	eIT + RT	P values
Count	6,564	4,547	2,017
Age at diagnosis, median [IQR]	64 [57–71]	64 [57–72]	63 [56–70]	<0.0001
Race				0.3059
White	5,363 (81.7%)	3,708 (81.5%)	1,655 (82.1%)
Black	681 (10.4%)	462 (10.2%)	219 (10.9%)
Hispanic	208 (3.2%)	154 (3.4%)	54 (2.7%)
Other	312 (4.7%)	223 (4.9%)	89 (4.4%)
Sex				0.2364
Female	3,118 (47.5%)	2,182 (48.0%)	936 (46.4%)
Male	3,446 (52.5%)	2,365 (52.0%)	1,081 (53.6%)
Insurance status				<0.0001
Private	2,565 (39.1%)	1,720 (37.8%)	845 (41.9%)
Medicare	3,031 (46.2%)	2,156 (47.4%)	875 (43.4%)
Medicaid	485 (7.4%)	311 (6.8%)	174 (8.6%)
Uninsured	198 (3.0%)	131 (2.9%)	67 (3.3%)
Other Gov't	90 (1.4%)	61 (1.3%)	29 (1.4%)
Unknown	195 (3.0%)	168 (3.7%)	27 (1.3%)
Facility type				0.0009
Comprehensive	2,883 (44.5%)	2,017 (44.9%)	866 (43.5%)
Academic	2,183 (33.7%)	1,548 (34.5%)	635 (31.8%)
Other	1,417 (21.9%)	925 (20.6%)	492 (24.7%)
Missing	81	57	24
Charlson comorbidity				0.4362
0	4,432 (67.5%)	3,052 (67.1%)	1,380 (68.4%)
1	1,559 (23.8%)	1,083 (23.8%)	476 (23.6%)
2	433 (6.6%)	308 (6.8%)	125 (6.2%)
≥3	140 (2.1%)	104 (2.3%)	36 (1.8%)
Histology				<.0001
Adenocarcinoma	5,240 (79.8%)	3,707 (81.5%)	1,533 (76.0%)
Large cell	104 (1.6%)	69 (1.5%)	35 (1.7%)
Non-small cell NOS	662 (10.1%)	442 (9.7%)	220 (10.9%)
Squamous cell	499 (7.6%)	292 (6.4%)	207 (10.3%)
Adenosquamous	59 (0.9%)	37 (0.8%)	22 (1.1%)
Number of organs with metastasis				<.0001
0	2,599 (39.6%)	1,924 (42.3%)	675 (33.5%)
1	2,699 (41.1%)	1,835 (40.4%)	864 (42.9%)
2	1,034 (15.7%)	642 (14.1%)	392 (19.4%)
3	212 (3.2%)	138 (3.0%)	74 (3.7%)
4	20 (0.3%)	8 (0.2%)	12 (0.6%)
Chemotherapy				0.4117
Yes	6,056 (92.4%)	4,187 (92.3%)	1,869 (92.8%)
No	495 (7.6%)	351 (7.7%)	144 (7.2%)
Missing	13	9	4

RT, radiotherapy; eIT, early-incorporation immunotherapy.